BioRevolution at Slush 2024

I had the incredible opportunity to witness INBRAIN Neuroelectronics take the stage and share their groundbreaking advancements in brain-computer interface (BCI) technology. Their presentation was nothing short of inspiring, showcasing how they are harnessing the power of graphene—a Nobel Prize-winning material—to redefine precision neurology.

The big news? INBRAIN just announced a $50M Series B funding round, led by imec.xpand and supported by key investors like the EIC IMPACT TRUST - EIC IMPACT FUND (Eastern Investment Centers) , Fond-ICO Next Tech, and more. This milestone also comes with additional backing from Merck KGaA to further the clinical development of their cutting-edge platform. Together, these developments position INBRAIN as a leader in the next generation of neural therapeutics.

What stood out most during the talk was their vision of combining high-resolution neural decoding with real-time modulation to address neurological disorders. With one in three people affected by these disorders—and many not responding to traditional therapies—their work represents hope for a better future. And the cherry on top? INBRAIN has already made history by successfully testing their graphene neural interface in human brains.

What struck me most was how Slush has embraced the biotechnological revolution by giving a platform to startups like INBRAIN. In a world where one in three people suffers from neurological disorders, the importance of biotech innovation cannot be overstated. Slush's commitment to amplifying these voices ensures that cutting-edge technologies get the visibility and collaboration opportunities they deserve.

Let’s keep pushing the boundaries of what’s possible! 🚀

—

Hi, I'm Damla 👋🏻

I am talking about BioRevolution & Biotech Trends in 2034 on LinkedIn

If what I say excites you, follow me and subscribe to my newsletter, BioRevolution : https://lnkd.in/d3VRhTG3